



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 53011

Title: Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature

Reviewer's code: 02476743

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor, Statistician

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: France

Manuscript submission date: 2020-01-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-23 03:14

Reviewer performed review: 2020-01-30 06:40

Review time: 7 Days and 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Overall comments: This case report was discussed the complete response to crizotinib in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer. There are several areas where the manuscript needs to be strengthened. Specific comments: 1.Statement of Ethics: In addition to Institutional Review Board approval, authors should also state that subject have given their written informed consent 2. More discussion regarding the medical policy implications of their findings would be essential for the use of methodology in medical decision making. 3.The authors should add the comments related to selection bias in this study to the perceived limitation subsection. Totally, I would like to congratulate the authors for the enthusiasm invested in this study. However, the manuscript does not reach the level of quality required for publication as original research without major revision in World Journal of Clinical Oncology.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 53011

Title: Complete response in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer: A case report and review of literature

Reviewer's code: 02498816

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: France

Manuscript submission date: 2020-01-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-19 00:22

Reviewer performed review: 2020-01-30 09:58

Review time: 11 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

I read this manuscript with interest. In addition, ALK-positive thyroid cancer is extremely rare. So I think that this case report seems to be important for medical clinician. However, I have several comments. 1) Authors should describe the response by using radiographic criteria.(RECIT criteria). Several reports showed the biological (or metabolic) complete response by ALK or EGFR-tyrosine -kinase inhibitor in patients with lung cancer. I think “Complete response to crizotinib by PET findings” is not essential in this paper. Title should be changed. 2) Authors should show the pathological findings of thyroid tumor and ALK positive pictures (IHC or FISH).



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 53011

Title: Complete response in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer: A case report and review of literature

Reviewer's code: 02476743

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor, Statistician

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: France

Manuscript submission date: 2020-01-18

Reviewer chosen by: Ying Dou

Reviewer accepted review: 2020-05-21 02:01

Reviewer performed review: 2020-05-22 01:50

Review time: 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Overall comments: This case report was discussed the complete response to crizotinib in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer. There are several areas where the manuscript needs to be strengthened. Specific comments: 1.Statement of Ethics: In addition to Institutional Review Board approval, authors should also state that subject have given their written informed consent 2. More discussion regarding the medical policy implications of their findings would be essential for the use of methodology in medical decision making. 3.The authors should add the comments related to selection bias in this study to the perceived limitation subsection. 4.Some references should be updated. Totally, I would like to congratulate the authors for the enthusiasm invested in this study. However, the manuscript does not reach the level of quality required for publication as original research without major revision in World Journal of Clinical Oncology.